Jacobs Levy Equity Management Inc. Has $1.53 Million Stake in Arcturus Therapeutics Holdings Inc. $ARCT

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in Arcturus Therapeutics by 20.6% in the first quarter, holding 144,141 shares valued at approximately $1.53 million.
• Arcturus Therapeutics reports a negative EPS of ($0.34) for the last quarter, surpassing consensus estimates, alongside a revenue of $28.30 million.
• Eight equities research analysts have rated Arcturus Therapeutics with a "Buy" rating, assigning a consensus price target of $50.57.

Jacobs Levy Equity Management Inc. increased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 20.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 144,141 shares of the biotechnology company's stock after buying an additional 24,583 shares during the period. Jacobs Levy Equity Management Inc. owned 0.53% of Arcturus Therapeutics worth $1,526,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ARCT. Byrne Asset Management LLC raised its stake in shares of Arcturus Therapeutics by 89.8% during the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after buying an additional 1,365 shares during the last quarter. US Bancorp DE raised its stake in shares of Arcturus Therapeutics by 218.9% during the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock worth $36,000 after buying an additional 2,329 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Arcturus Therapeutics by 40,686.2% during the first quarter. Russell Investments Group Ltd. now owns 11,828 shares of the biotechnology company's stock worth $125,000 after buying an additional 11,799 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Arcturus Therapeutics during the first quarter worth approximately $128,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Arcturus Therapeutics by 9.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company's stock worth $156,000 after buying an additional 1,232 shares during the last quarter. 94.54% of the stock is owned by institutional investors.

Arcturus Therapeutics Stock Up 0.3%

Shares of ARCT stock opened at $17.99 on Thursday. The firm has a fifty day moving average of $15.22 and a 200-day moving average of $13.40. Arcturus Therapeutics Holdings Inc. has a 12-month low of $8.04 and a 12-month high of $25.88. The company has a market capitalization of $488.61 million, a price-to-earnings ratio of -8.07 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.77. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. The company had revenue of $28.30 million during the quarter, compared to the consensus estimate of $17.64 million. On average, equities analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ARCT. HC Wainwright began coverage on shares of Arcturus Therapeutics in a research note on Thursday, September 4th. They set a "buy" rating and a $60.00 price target for the company. Leerink Partners dropped their price target on shares of Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating for the company in a research note on Friday, August 22nd. Citigroup reaffirmed a "buy" rating and issued a $49.00 target price (up previously from $47.00) on shares of Arcturus Therapeutics in a research note on Tuesday, August 12th. Wall Street Zen raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Arcturus Therapeutics has a consensus rating of "Buy" and a consensus price target of $50.57.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.